In addition, it has been found that CRC cells usually develop along the mitogen-activated protein kinase (MAPK) pathway, while MAPK activity will drive the cellular trajectory of cancer cells, and the targeting of EGFR-BRAF-MEK in tumor-like organs depends on acquired KRAS/BRAF mutations and induced cellular plasticity, which affects signal transduction and gene expression (15). This evidence concerns the gene BRAF and neoplasm.